BSE filing, NSE: TRITON. Summary written from the filing by ALFA Finder's alert engine.
Homre Ltd: key numbers
- Share price
- ₹1.67
- Market cap
- ₹33.38 Cr
- Revenue (annual)
- ₹15.29 Cr
- Net profit (annual)
- ₹-0.02 Cr
- P/E (TTM)
- 42.1×Sector 49.0×
- Promoter holding
- 64.03%-0.96% QoQ
- FII holding
- 0.23%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Homre Ltd
All →Homre Q2 FY27 Results: Net Profit ₹0.7 Cr, Up 250.0% YoY
Homre Ltd reported revenue from operations of ₹20.9 Cr (+770.8% YoY) and net profit of ₹0.7 Cr (+250.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹0.7 Cr · +250.0% YoY
Homre Management Change
HOMRE Ltd submitted the previously omitted resignation letter of Company Secretary Pratibha Sharma under Reg 30. Her role as Compliance Officer ended 11 September 2026.
Homre Other Announcement
Homre Limited has filed the mandatory quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the period ended September 30, 2026.
Homre Board Meeting Date
HOMRE Ltd has scheduled its board meeting for October 16, 2026 to approve unaudited H1 FY27 results. The trading window closes from October 1 pending results.
Homre Annual General Meeting
HOMRE Limited submitted clarification and proceedings for its 36th Annual General Meeting held on September 24, 2026. The company cited technical issues for the initial reporting delay.
Homre Annual General Meeting
Homre Limited concluded its 36th Annual General Meeting on September 24, 2026. The meeting approved several special business resolutions, including an ESOP scheme and a preferential warrant issue.
- Value
- ₹12.50 Cr
Other board meeting date announcements
All →Patel Engineering Board Meeting Date
Patel Engineering has scheduled its Board meeting for November 5, 2026, to approve Q1 and H1 FY27 unaudited results. No financial figures or decisions are reported in this advance notice.
GKB Ophthalmics Board Meeting Date
GKB Ophthalmics scheduled its Board Meeting for November 12, 2026. The meeting will consider approving unaudited results for the September 30, 2026 quarter and half year.
Bombay Oxygen Investments Board Meeting Date
Board meeting scheduled for Nov 6, 2026 to approve Q1 and H1 FY27 unaudited results. Trading window closed for insiders Oct 1–Nov 8, 2026.
OCCL Board Meeting Date
OCCL Ltd has scheduled its Board meeting for 6 November 2026 to consider Q1 FY27 unaudited results and a possible interim dividend. The trading window for designated persons closed from 1 October 2026.
TCM Board Meeting Date
TCM Limited intimated a Board meeting for 06/11/2026 to approve Q2 FY27 results. The trading window will reopen 48 hours after the results declaration.
Mercury Laboratories Board Meeting Date
Mercury Laboratories scheduled its Board meeting for November 5, 2026, to approve Q2/H1 FY27 results. Trading window remains closed until 48 hours post-announcement.